These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25361987)

  • 1. 90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas.
    Bouabdallah K; Furst S; Asselineau J; Chevalier P; Tournilhac O; Ceballos P; Vigouroux S; Tabrizi R; Doussau A; Bouabdallah R; Mohty M; Le Gouill S; Blaise D; Milpied N
    Ann Oncol; 2015 Jan; 26(1):193-198. PubMed ID: 25361987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
    Vigouroux S; Michallet M; Porcher R; Attal M; Ades L; Bernard M; Blaise D; Tabrizi R; Garban F; Cassuto JP; Chevalier P; Facon T; Ifrah N; Renaud M; Tilly H; Vernant JP; Kuentz M; Bourhis JH; Bordigoni P; Deconinck E; Lioure B; Socié G; Milpied N;
    Haematologica; 2007 May; 92(5):627-34. PubMed ID: 17488686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial.
    Cabrero M; Martin A; Briones J; Gayoso J; Jarque I; López J; Grande C; Heras I; Arranz R; Bernal T; Perez-Lopez E; López-Godino O; Conde E; Caballero D
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):53-59. PubMed ID: 27771496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using
    Mei M; Palmer J; Tsai NN; Simpson J; O'Hearn J; Stein A; Forman S; Spielberger R; Cai JL; Htut M; Nakamura R; Al Malki MM; Herrera A; Wong J; Nademanee A
    Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):e268-e276. PubMed ID: 37301631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens.
    Bertz H; Illerhaus G; Veelken H; Finke J
    Ann Oncol; 2002 Jan; 13(1):135-9. PubMed ID: 11863095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unmanipulated Haploidentical Reduced-Intensity Stem Cell Transplantation Using Fludarabine, Busulfan, Low-Dose Antithymocyte Globulin, and Steroids for Patients in Non-Complete Remission or at High Risk of Relapse: A Prospective Multicenter Phase I/II Study in Japan.
    Ikegame K; Yoshida T; Yoshihara S; Daimon T; Shimizu H; Maeda Y; Ueda Y; Kaida K; Ishii S; Taniguchi K; Okada M; Tamaki H; Okumura H; Kaya H; Kurokawa T; Kodera Y; Taniguchi S; Kanda Y; Ogawa H
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1495-505. PubMed ID: 25921715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
    Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Krejci M; Brychtova Y; Doubek M; Tomiska M; Navratil M; Racil Z; Dvorakova D; Horky O; Lengerova M; Pospisilova S; Mayer J
    Neoplasma; 2011; 58(5):406-14. PubMed ID: 21744994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
    Kekre N; Marquez-Malaver FJ; Cabrero M; Piñana J; Esquirol A; Soiffer RJ; Caballero D; Terol MJ; Martino R; Antin JH; Lopez-Corral L; Solano C; Armand P; Pérez-Simon JA
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1808-1815. PubMed ID: 27470290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Follow-Up of
    Puronen CE; Cassaday RD; Stevenson PA; Sandmaier BM; Flowers ME; Green DJ; Maloney DG; Storb RF; Press OW; Gopal AK
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2211-2215. PubMed ID: 30454872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial.
    Mohty M; Malard F; Blaise D; Milpied N; Furst S; Tabrizi R; Guillaume T; Vigouroux S; El-Cheikh J; Delaunay J; Le Gouill S; Moreau P; Labopin M; Chevallier P
    Cancer; 2015 Feb; 121(4):562-9. PubMed ID: 25283774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).
    Le Bourgeois A; Lestang E; Guillaume T; Delaunay J; Ayari S; Blin N; Clavert A; Tessoulin B; Dubruille V; Mahe B; Roland V; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Chevallier P
    Eur J Haematol; 2013 Mar; 90(3):177-86. PubMed ID: 23301689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
    Kang BW; Kim WS; Kim C; Jang G; Lee SS; Choi YH; Lee DH; Kim SW; Kim S; Ryu JS; Huh J; Lee JS; Suh C
    Invest New Drugs; 2010 Aug; 28(4):516-22. PubMed ID: 19547918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.
    Gopal AK; Guthrie KA; Rajendran J; Pagel JM; Oliveira G; Maloney DG; Matesan MC; Storb RF; Press OW
    Blood; 2011 Jul; 118(4):1132-9. PubMed ID: 21508413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
    Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.
    Shimoni A; Zwas ST; Oksman Y; Hardan I; Shem-Tov N; Yerushalmi R; Avigdor A; Ben-Bassat I; Nagler A
    Exp Hematol; 2007 Apr; 35(4):534-40. PubMed ID: 17379063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.